NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Total Liabilities
Everything the company owes to creditors and other parties.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 21.5% from a year ago
Total liabilities stood at $25.72M at the end of Q1 FY2026, down 21.5% from a year earlier and down 11.0% from the prior quarter. Over 3 fiscal years it compounded at +16.2% a year.
Context
- Total liabilities amounted to 216.1% of total assets at the end of Q1 FY2026, down 215.4 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -21.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 28.89M USD
- Year-over-year change
- +7.5%
- 4-year CAGR
- +24.8%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.89M | +7.5% |
| FY2024 | 2024-12-31 | 26.87M | +41.1% |
| FY2023 | 2023-12-31 | 19.05M | +3.5% |
| FY2022 | 2022-12-31 | 18.41M | +54.4% |
| FY2021 | 2021-12-31 | 11.92M | — |
Total Liabilities vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 total liabilities of $25.72M is the 4th highest of the 9 companies compared; the peer median is $15.39M.
- Its year-over-year change of -21.5% is the 5th highest of 9, against a peer median of -29.3%.
- Total liabilities amounts to 216.1% of total assets for NRXP, versus a peer median of 31.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $397.06M | +19.0% | +2.3% | 302.1% | |
| Mar 2026 | $61.81M | -17.8% | -29.4% | 18.9% | |
| Mar 2026 | $50.89M | -1.3% | +36.9% | 232.4% | |
| Mar 2026 | $25.72M | -21.5% | +16.2% | 216.1% | |
| Mar 2026 | $21.52M | +31.8% | -15.1% | 38.3% | |
| Mar 2026 | $9.27M | -40.9% | -14.9% | 30.0% | |
| Jun 2026 | $7.86M | -84.6% | +5.6% | 32.6% | |
| Mar 2026 | $3.6M | -41.5% | -58.6% | 5.7% | |
| Mar 2026 | $390.53K | -93.5% | -15.5% | 2.0% | |
| Peer median (excluding NRXP) | $15.39M | -29.3% | -15.0% | 31.3% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.